Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease

Sevelamer carbonate (Renvela ® ), a buffered form of sevelamer hydrochloride (Renagel ® ), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CK...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 2014-05, Vol.74 (7), p.771-792
Hauptverfasser: Perry, Caroline M., Plosker, Greg L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 792
container_issue 7
container_start_page 771
container_title Drugs (New York, N.Y.)
container_volume 74
creator Perry, Caroline M.
Plosker, Greg L.
description Sevelamer carbonate (Renvela ® ), a buffered form of sevelamer hydrochloride (Renagel ® ), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.
doi_str_mv 10.1007/s40265-014-0215-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1642615228</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1528340671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-b4ad76110fa195e7f2eb7ccf44d2d7e83a0d9694b10467af752d4b8d9f81fb743</originalsourceid><addsrcrecordid>eNqFkUuLFDEURoMoTjv6A9xIQAQ3pbmpPKrcNe1jxAHBx8JVSFVu7Az1mqRqhv73puj2gSCuQpJzv9ybQ8hjYC-AMf0yCcaVLBiIgnGQhb5DNgC6LqCW7C7ZMAa8UErpM_Igpat1W8v6PjnjogKQQm3It894g53tMdKdjc042Blf0S39hDcBb2kY6MVhwjjtxzTt7WyxD3Y93bqlmxO9DfOe7vZxHEJLPwQ34IG-Dgltwofknrddwken9Zx8ffvmy-6iuPz47v1ue1m0opRz0QjrtAJg3uauUXuOjW5bL4TjTmNVWuZqVYsGmFDaei25E03lal-Bb7Qoz8nzY-4Ux-sF02z6kFrsOjvguCQDSnAFkvPq_6jMkGBKQ0af_oVejUsc8iA5kPNS1fkDMwVHqo1jShG9mWLobTwYYGZVZI6KTFZkVkVG55onp-Sl6dH9qvjpJAPPToBNre18tEMb0m-uUqysYB2cH7mUr4bvGP9o8Z-v_wChaacG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1622369115</pqid></control><display><type>article</type><title>Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Perry, Caroline M. ; Plosker, Greg L.</creator><creatorcontrib>Perry, Caroline M. ; Plosker, Greg L.</creatorcontrib><description>Sevelamer carbonate (Renvela ® ), a buffered form of sevelamer hydrochloride (Renagel ® ), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-014-0215-7</identifier><identifier>PMID: 24811546</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Acidosis ; Adis Drug Evaluation ; Adult ; Biological and medical sciences ; Calcification ; Cardiovascular disease ; Cholesterol ; Hemodialysis ; Humans ; Hyperphosphatemia - drug therapy ; Internal Medicine ; Kidney diseases ; Kidneys ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Metabolism ; Mortality ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Pharmacodynamics ; Pharmacology/Toxicology ; Pharmacotherapy ; Polyamines - administration &amp; dosage ; Polyamines - pharmacology ; Polyamines - therapeutic use ; Renal failure ; Renal Insufficiency, Chronic - drug therapy ; Sevelamer ; Urinary system involvement in other diseases. Miscellaneous</subject><ispartof>Drugs (New York, N.Y.), 2014-05, Vol.74 (7), p.771-792</ispartof><rights>Springer International Publishing Switzerland 2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Wolters Kluwer Health Adis International May 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-b4ad76110fa195e7f2eb7ccf44d2d7e83a0d9694b10467af752d4b8d9f81fb743</citedby><cites>FETCH-LOGICAL-c435t-b4ad76110fa195e7f2eb7ccf44d2d7e83a0d9694b10467af752d4b8d9f81fb743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-014-0215-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-014-0215-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28603814$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24811546$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perry, Caroline M.</creatorcontrib><creatorcontrib>Plosker, Greg L.</creatorcontrib><title>Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Sevelamer carbonate (Renvela ® ), a buffered form of sevelamer hydrochloride (Renagel ® ), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.</description><subject>Acidosis</subject><subject>Adis Drug Evaluation</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Calcification</subject><subject>Cardiovascular disease</subject><subject>Cholesterol</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Hyperphosphatemia - drug therapy</subject><subject>Internal Medicine</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolism</subject><subject>Mortality</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Pharmacodynamics</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Polyamines - administration &amp; dosage</subject><subject>Polyamines - pharmacology</subject><subject>Polyamines - therapeutic use</subject><subject>Renal failure</subject><subject>Renal Insufficiency, Chronic - drug therapy</subject><subject>Sevelamer</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkUuLFDEURoMoTjv6A9xIQAQ3pbmpPKrcNe1jxAHBx8JVSFVu7Az1mqRqhv73puj2gSCuQpJzv9ybQ8hjYC-AMf0yCcaVLBiIgnGQhb5DNgC6LqCW7C7ZMAa8UErpM_Igpat1W8v6PjnjogKQQm3It894g53tMdKdjc042Blf0S39hDcBb2kY6MVhwjjtxzTt7WyxD3Y93bqlmxO9DfOe7vZxHEJLPwQ34IG-Dgltwofknrddwken9Zx8ffvmy-6iuPz47v1ue1m0opRz0QjrtAJg3uauUXuOjW5bL4TjTmNVWuZqVYsGmFDaei25E03lal-Bb7Qoz8nzY-4Ux-sF02z6kFrsOjvguCQDSnAFkvPq_6jMkGBKQ0af_oVejUsc8iA5kPNS1fkDMwVHqo1jShG9mWLobTwYYGZVZI6KTFZkVkVG55onp-Sl6dH9qvjpJAPPToBNre18tEMb0m-uUqysYB2cH7mUr4bvGP9o8Z-v_wChaacG</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Perry, Caroline M.</creator><creator>Plosker, Greg L.</creator><general>Springer International Publishing</general><general>Adis International</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7U1</scope><scope>7U2</scope></search><sort><creationdate>20140501</creationdate><title>Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease</title><author>Perry, Caroline M. ; Plosker, Greg L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-b4ad76110fa195e7f2eb7ccf44d2d7e83a0d9694b10467af752d4b8d9f81fb743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acidosis</topic><topic>Adis Drug Evaluation</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Calcification</topic><topic>Cardiovascular disease</topic><topic>Cholesterol</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Hyperphosphatemia - drug therapy</topic><topic>Internal Medicine</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolism</topic><topic>Mortality</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Pharmacodynamics</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Polyamines - administration &amp; dosage</topic><topic>Polyamines - pharmacology</topic><topic>Polyamines - therapeutic use</topic><topic>Renal failure</topic><topic>Renal Insufficiency, Chronic - drug therapy</topic><topic>Sevelamer</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perry, Caroline M.</creatorcontrib><creatorcontrib>Plosker, Greg L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perry, Caroline M.</au><au>Plosker, Greg L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>74</volume><issue>7</issue><spage>771</spage><epage>792</epage><pages>771-792</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><coden>DRUGAY</coden><abstract>Sevelamer carbonate (Renvela ® ), a buffered form of sevelamer hydrochloride (Renagel ® ), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do not require dialysis with serum phosphate levels ≥1.78 mmol/L, whereas in the USA sevelamer carbonate is approved in adult CKD patients who require dialysis. Sevelamer carbonate and sevelamer hydrochloride achieved similar reductions in serum phosphate levels in randomized comparative trials in patients with CKD receiving haemodialysis; sevelamer carbonate also reduced serum phosphate levels in noncomparative studies in CKD patients not requiring dialysis. The most common adverse events with sevelamer carbonate are gastrointestinal in nature. Sevelamer has pleiotropic effects, such as improving the serum lipid profile and attenuating endothelial and cardiovascular risk factors in CKD. All formulations of sevelamer have markedly higher acquisition costs than calcium-based phosphate binders. Cost-effectiveness analyses focusing specifically on sevelamer carbonate have not been conducted, and those based on clinical trial data with sevelamer hydrochloride have provided both favourable and unfavourable results compared with calcium-based phosphate binders, reflecting heterogeneity between modelled analyses in terms of data sources, assumptions, comparators, geographical regions, type of costs included and other factors. Although well-designed studies evaluating the impact of phosphate binders on hard clinical endpoints appear to be warranted, sevelamer carbonate may be particularly useful for the treatment of patients at risk of metabolic acidosis (offering advantages over sevelamer hydrochloride in this regard) and for individuals requiring treatment with a phosphate binding agent that does not contain aluminium or calcium.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>24811546</pmid><doi>10.1007/s40265-014-0215-7</doi><tpages>22</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0012-6667
ispartof Drugs (New York, N.Y.), 2014-05, Vol.74 (7), p.771-792
issn 0012-6667
1179-1950
language eng
recordid cdi_proquest_miscellaneous_1642615228
source MEDLINE; SpringerLink Journals
subjects Acidosis
Adis Drug Evaluation
Adult
Biological and medical sciences
Calcification
Cardiovascular disease
Cholesterol
Hemodialysis
Humans
Hyperphosphatemia - drug therapy
Internal Medicine
Kidney diseases
Kidneys
Medical sciences
Medicine
Medicine & Public Health
Metabolism
Mortality
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Pharmacodynamics
Pharmacology/Toxicology
Pharmacotherapy
Polyamines - administration & dosage
Polyamines - pharmacology
Polyamines - therapeutic use
Renal failure
Renal Insufficiency, Chronic - drug therapy
Sevelamer
Urinary system involvement in other diseases. Miscellaneous
title Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T09%3A10%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sevelamer%20Carbonate:%20A%20Review%20in%20Hyperphosphataemia%20in%20Adults%20with%20Chronic%20Kidney%20Disease&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Perry,%20Caroline%20M.&rft.date=2014-05-01&rft.volume=74&rft.issue=7&rft.spage=771&rft.epage=792&rft.pages=771-792&rft.issn=0012-6667&rft.eissn=1179-1950&rft.coden=DRUGAY&rft_id=info:doi/10.1007/s40265-014-0215-7&rft_dat=%3Cproquest_cross%3E1528340671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1622369115&rft_id=info:pmid/24811546&rfr_iscdi=true